Evidence and Research for Cabotegravir (CAB-LA)
Research shows that CAB-LA is safe and effective and provides a longer-acting alternative to daily oral PrEP.
While both access and availability to oral PrEP has increased across the world in recent years, not everyone is able to take a daily pill as instructed.
CAB-LA is an alternative, injectable PrEP option. Efficacy data from phase III clinical studies (HPTN 083 and HPTN 084) show it is safe, well-tolerated, and effective. In MSM and transgender women there was a 66 percent reduction in HIV acquisition in study participants given CAB-LA compared to TDF/FTC and an 89 percent reduction in HIV acquisition in cisgender women.
Read below to find out more about: